VolitionRx's (VNRX) Buy Rating Reaffirmed at D. Boral Capital

Key Points

• D. Boral Capital has reaffirmed a "Buy" rating for VolitionRx (NYSE: VNRX) with a price target of $5.00.
• The company's stock currently has a consensus rating of "Buy" among analysts, with a consensus price target of $3.50.
• Insider activity has increased, with both the CEO and a director purchasing shares, signaling confidence in the company's prospects.

VolitionRx (NYSE:VNRX - Get Free Report)'s stock had its "buy" rating restated by research analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $5.00 target price on the stock.

Several other analysts have also recently issued reports on the company. Wall Street Zen initiated coverage on VolitionRx in a research note on Thursday, May 15th. They set a "sell" rating on the stock. Jones Trading upgraded VolitionRx to a "strong-buy" rating and set a $3.00 price objective on the stock in a research note on Tuesday, June 10th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $3.50.

VolitionRx Price Performance

VNRX traded up $0.03 on Wednesday, reaching $0.66. The company's stock had a trading volume of 273,752 shares, compared to its average volume of 198,505. The stock has a market cap of $70.59 million, a price-to-earnings ratio of -1.82 and a beta of 1.27. VolitionRx has a 1 year low of $0.40 and a 1 year high of $0.94. The business's 50 day moving average is $0.67 and its 200 day moving average is $0.60.

Insider Buying and Selling

In other news, Director Guy Archibald Innes purchased 78,125 shares of the firm's stock in a transaction on Tuesday, August 5th. The stock was purchased at an average cost of $0.64 per share, with a total value of $50,000.00. Following the purchase, the director owned 966,814 shares in the company, valued at $618,760.96. This trade represents a 8.79% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Cameron John Reynolds purchased 78,125 shares of the firm's stock in a transaction on Tuesday, August 5th. The shares were purchased at an average cost of $0.64 per share, with a total value of $50,000.00. Following the completion of the purchase, the chief executive officer owned 2,609,847 shares in the company, valued at $1,670,302.08. This represents a 3.09% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 10.40% of the company's stock.

Hedge Funds Weigh In On VolitionRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VNRX. Blair William & Co. IL bought a new position in VolitionRx during the 2nd quarter valued at $30,000. Millennium Management LLC bought a new position in VolitionRx during the 4th quarter valued at $36,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of VolitionRx during the 2nd quarter worth $52,000. Northern Trust Corp boosted its stake in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after acquiring an additional 28,579 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC boosted its stake in shares of VolitionRx by 42.8% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock worth $153,000 after acquiring an additional 60,209 shares in the last quarter. 8.09% of the stock is owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.